|
Post by celo on Apr 13, 2018 15:11:16 GMT -5
as far as improve insurance coverage/marketing, Beyond Type One Events Schedule in CA and MN. /photo/1?tfw_site=proboards&ref_src=twsrc%5Etfw&ref_url=http%3A%2F%2Fmnkd.proboards.com%2Fthread%2F5902%2Fmnkd-on-twitter%3Fpage%3D69 Dr. Kendall has Minnesota ties. United Health based out of Minnesota? Looks like we have something to see headway with united health. beyondtype1.org/slipstreams2018/goyocafe pointed out the sponsors. Is this part of the new marketing? Thank you for the thread compound. I think it is great that mannkind is sponsoring this event. However, because this event is about diabetes and their one diabetic drug is Afrezza, they need to have Afrezza as the sponsor. They need an advertisement on the webpage similar to Dexcom. Dexcom says continuous glucose monitoring. Perfect. Mannkind needs Afrezza, with a statement similar to the following: Feel like not being a diabetic anymore with the world's greatest insulin. I mean something EYE POPPING. Not mannkind. We are failing and Mannkind needs to change.
|
|
|
Post by akemp3000 on Apr 13, 2018 15:11:57 GMT -5
Some comments beg the question why some posters are even here...no, not really.
|
|
|
Post by peppy on Apr 13, 2018 15:21:19 GMT -5
as far as improve insurance coverage/marketing, Beyond Type One Events Schedule in CA and MN. /photo/1?tfw_site=proboards&ref_src=twsrc%5Etfw&ref_url=http%3A%2F%2Fmnkd.proboards.com%2Fthread%2F5902%2Fmnkd-on-twitter%3Fpage%3D69 Dr. Kendall has Minnesota ties. United Health based out of Minnesota? Looks like we have something to see headway with united health. beyondtype1.org/slipstreams2018/goyocafe pointed out the sponsors. Is this part of the new marketing? Thank you for the thread compound. I think it is great that mannkind is sponsoring this event. However, because this event is about diabetes and their one diabetic drug is Afrezza, they need to have Afrezza as the sponsor. They need an advertisement on the webpage similar to Dexcom. Dexcom says continuous glucose monitoring. Perfect. Mannkind needs Afrezza, with a statement similar to the following: Feel like not being a diabetic anymore with the world's greatest insulin. I mean something EYE POPPING. Not mannkind. We are failing and Mannkind needs to change. Celo, I recall Mike saying in Monaco, "when physicians see the continuous glucose monitors, they can't believe it." The physicians get to see them. STAT. It should draw them in. Physicians can read monitors across a room. Feel like not being a diabetic anymore with the world's greatest insulin. Seeing is believing.
|
|
|
Post by bosephe on Apr 13, 2018 19:18:27 GMT -5
One drop (app support + cash program) I would like to see more progress made on efforts like this that can reduce the involvement of insurance companies. Right now the fate of the company seems to be in the hands of insurance companies.
|
|
|
Post by dreamboatcruise on Apr 13, 2018 19:35:31 GMT -5
One drop (app support + cash program) I would like to see more progress made on efforts like this that can reduce the involvement of insurance companies. Right now the fate of the company seems to be in the hands of insurance companies. Unless MNKD were to basically give away Afrezza (e.g. 1/10th what they charge now), there would likely be far fewer people that could afford to pay totally themselves than the number that currently have insurance coverage for Afrezza. Like it or not, to come even close to recovering the cost of developing a new drug like Afrezza (or in MNKD's situation, merely getting out from under the mountain of debt left from development), the drug must be priced such that few could afford it paying cash... and thus the success is in the hands of the insurance companies.
|
|
|
Post by sellhighdrinklow on Apr 13, 2018 20:30:21 GMT -5
I think it is great that mannkind is sponsoring this event. However, because this event is about diabetes and their one diabetic drug is Afrezza, they need to have Afrezza as the sponsor. They need an advertisement on the webpage similar to Dexcom. Dexcom says continuous glucose monitoring. Perfect. Mannkind needs Afrezza, with a statement similar to the following: Feel like not being a diabetic anymore with the world's greatest insulin. I mean something EYE POPPING. Not mannkind. We are failing and Mannkind needs to change. Celo, I recall Mike saying in Monaco, "when physicians see the continuous glucose monitors, they can't believe it." The physicians get to see them. STAT. It should draw them in. Physicians can read monitors across a room. Feel like not being a diabetic anymore with the world's greatest insulin. Seeing is believing. Fact. Three years of documentation by me on Afrezza. This is my life. 40-years type 1.
|
|
|
Post by straightly on Apr 14, 2018 11:05:00 GMT -5
as far as improve insurance coverage/marketing, Beyond Type One Events Schedule in CA and MN. /photo/1?tfw_site=proboards&ref_src=twsrc%5Etfw&ref_url=http%3A%2F%2Fmnkd.proboards.com%2Fthread%2F5902%2Fmnkd-on-twitter%3Fpage%3D69 Dr. Kendall has Minnesota ties. United Health based out of Minnesota? Looks like we have something to see headway with united health. beyondtype1.org/slipstreams2018/goyocafe pointed out the sponsors. Is this part of the new marketing? Thank you for the thread compound. I think it is great that mannkind is sponsoring this event. However, because this event is about diabetes and their one diabetic drug is Afrezza, they need to have Afrezza as the sponsor. They need an advertisement on the webpage similar to Dexcom. Dexcom says continuous glucose monitoring. Perfect. Mannkind needs Afrezza, with a statement similar to the following: Feel like not being a diabetic anymore with the world's greatest insulin. I mean something EYE POPPING. Not mannkind. We are failing and Mannkind needs to change. Talking about hitting the nail right on the head. We do not have money to promote two brands so let's focus one label.
|
|
|
Post by agedhippie on Apr 14, 2018 11:29:59 GMT -5
One drop (app support + cash program) I would like to see more progress made on efforts like this that can reduce the involvement of insurance companies. Right now the fate of the company seems to be in the hands of insurance companies. If Mannkind wants a cash program they are going to have to dramatically lower the price. Sanofi have just announced that they are selling their Humalog biosimilar to everyone regardless of insurance status for $149 per box of 5 pens. That is 1500u which is roughly equivalent to to two boxes of Afrezza costing about $1200 without insurance making Afrezza eight times more expensive. Sanofi have the same deal on Lantus. Diatribe - Admelog, First “Biosimilar” Mealtime Insulin, Launches with New Savings Program
|
|
|
Post by slugworth008 on Apr 14, 2018 11:38:44 GMT -5
Here is my forecast Q1 - Dilution Q2 - Dilution Q3 - Dilution Q4 - Dilution. For those who voted to authorize 140 mil shares, plan to reduce your networth. Until I / we actually see something with upfront cash - Yep.
|
|
|
Post by peppy on Apr 14, 2018 11:50:40 GMT -5
One drop (app support + cash program) I would like to see more progress made on efforts like this that can reduce the involvement of insurance companies. Right now the fate of the company seems to be in the hands of insurance companies. If Mannkind wants a cash program they are going to have to dramatically lower the price. Sanofi have just announced that they are selling their Humalog biosimilar to everyone regardless of insurance status for $149 per box of 5 pens. That is 1500u which is roughly equivalent to to two boxes of Afrezza costing about $1200 without insurance making Afrezza eight times more expensive. Sanofi have the same deal on Lantus. Diatribe - Admelog, First “Biosimilar” Mealtime Insulin, Launches with New Savings Programyeah, RAA, Humalog, is a second grade insulin. they make people take it subq, it is slow to act, only gives phase two. The stuff is chit. This Fiasp, Humalog, close enough to drive the point aged. Old and lousy, vs new and improved. There will be a percentage of the population that can recognize what they are seeing, Have the insurance coverage and can afford it. With the STAT study, the graphics can be seen. too bad the facts are starting to out weigh apathy.
|
|
|
Post by agedhippie on Apr 14, 2018 12:17:19 GMT -5
If Mannkind wants a cash program they are going to have to dramatically lower the price. Sanofi have just announced that they are selling their Humalog biosimilar to everyone regardless of insurance status for $149 per box of 5 pens. That is 1500u which is roughly equivalent to to two boxes of Afrezza costing about $1200 without insurance making Afrezza eight times more expensive. Sanofi have the same deal on Lantus. Diatribe - Admelog, First “Biosimilar” Mealtime Insulin, Launches with New Savings Programyeah, RAA, Humalog, is a second grade insulin. they make people take it subq, it is slow to act, only gives phase two. The stuff is chit. This Fiasp, Humalog, close enough to drive the point aged. Old and lousy, vs new and improved. There will be a percentage of the population that can recognize what they are seeing, Have the insurance coverage and can afford it. With the STAT study, the graphics can be seen. ... too bad the facts are starting to out weigh apathy. This comes down to the reason why there is any market at all for Regular and NPH insulin - cost. For people with no insurance or high deductible plans do you want to pay 8 times more for Afrezza than for an RAA that is hardly stellar but is good enough? Some of this is apathy, some of this is not seeing the case. Afrezza is a superior insulin, but than has been true since day one and yet here we are three years later so obviously the message used to date has not worked. My numbers are good enough for whether to swap or not is not to be exactly a pressing issue. I see people though who absolutely should be on Afrezza and I cannot persuade them to move. It's the perfect insulin for anyone with gastroparesis and a CGM, for pregnant Type 1s or women with gestational diabetes, for people with absorption issues. To be honest it frustrates me as well that I cannot get them to move.
|
|